SRPT stock forecast, quote, news & analysis
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders... Show more
Why Sarepta Therapeutics (SRPT) Is Down -6% in the Last 30 Days
Key Takeaways
- SRPT stock declined approximately -6% over the past 30 days amid ongoing concerns over Elevidys sales slowdown and regulatory hurdles.
- Over the past quarter, the stock fell around -19%, driven by clinical trial setbacks, patient safety issues, and weaker-than-expected revenue guidance.
- Major factors include Elevidys shipment pauses following patient deaths, trial failures for approved DMD drugs, and analyst downgrades reflecting pipeline risks.
- Recent positive FDA feedback on confirmatory data provided minor support but failed to reverse the downtrend.
- Biotech sector volatility and Sarepta's high beta amplified price movements in a challenging macro environment for gene therapies.
Sarepta Therapeutics (SRPT) Company Overview and Market Position
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD). Its core business model centers on RNA-targeted therapeutics, gene therapies, and siRNA platforms, with key products like EXONDYS 51, VYONDYS 53, AMONDYS 45, and the gene therapy ELEVIDYS targeting specific DMD mutations. Operating in the competitive biotech sector against players like Roche and Novartis, Sarepta holds a leading position in exon-skipping therapies for DMD but faces intense scrutiny on gene therapy safety and efficacy. These fundamentals expose the stock to regulatory and clinical risks, explaining recent price pressure from Elevidys-related setbacks amid a narrowing addressable market.
Sarepta Therapeutics (SRPT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SRPT stock declined from around $18.80 (late February close) to $17.61 (March 24 close), marking a -6% drop. The movement was volatile and range-bound, dipping to lows near $15.90 in early March before a partial rebound, reflecting choppy trading amid mixed news flow.
For the past quarter, the stock fell sharply from approximately $22.00 (late December) to $17.61, a -19% decrease. This trend-driven downside featured steep declines tied to specific catalysts, with heightened volatility as shares tested 52-week lows around $10.42 earlier in the period.
What Drove SRPT Stock Price in the Last 30 Days
The 30-day downturn stemmed primarily from persistent Elevidys challenges, including suspended shipments to non-ambulatory patients after FDA concerns over three patient deaths linked to acute liver failure. Q4 2025 preliminary results showed Elevidys sales missing estimates at $110 million, blamed on flu season and label restrictions, eroding investor confidence. Early March saw shares hit $15.87 lows amid broader biotech weakness. A brief uptick followed FDA agreement to review ESSENCE Phase 3 data for traditional approvals of AMONDYS 45 and VYONDYS 53, but weak sales outlook capped gains. Analyst actions, including BofA's Underperform reiteration citing regulatory risks, further pressured sentiment.
What Drove SRPT Stock Performance Over the Last Quarter
The quarterly decline was fueled by cascading negative events, starting with July 2025 FDA requests to halt Elevidys shipments and clinical holds after three deaths, triggering a 30-40% plunge and multiple downgrades. November's trial failure in confirmatory studies for two approved DMD drugs, coupled with lowered Elevidys forecasts, caused another 30% drop, highlighting pipeline fragility. Macro factors like biotech sector rotation amid rising rates and inflation squeezed valuations, while institutional selling amplified the slide. Cost-cutting and pipeline refocus offered some stabilization, but cumulative safety and revenue risks dominated, pushing shares toward yearly lows.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from hundreds available on the platform, which trade thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance based on metrics like win rate, profit factor, and risk-adjusted returns. Strategies range from day trading and swing trading to long-term trend following, with timeframes spanning intraday to monthly holds. Each bot includes detailed stats, backtests, and live trading records, helping investors identify relevant tools for stocks like SRPT. Explore the page to discover bots tailored to current market trends and potentially enhance your stock analysis.
SRPT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor FDA outcomes on supplemental applications for AMONDYS 45 and VYONDYS 53 by late April, including ESSENCE data review. Upcoming EMBARK study updates at ASGCT and ENDEAVOR Cohort 8 enrollment for Elevidys in non-ambulatory patients could sway sentiment. Pipeline progress in siRNA programs like SRP-1001 and SRP-1003, plus LGMD therapies, remains key amid safety scrutiny. Macro trends in biotech funding, interest rates, and regulatory shifts for gene therapies will influence sector flows. Risks include further Elevidys label changes or sales misses, while catalysts like positive AdCom votes or partnerships could drive volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
SRPT in downward trend: 10-day moving average broke below 50-day moving average on May 18, 2026
The 10-day moving average for SRPT crossed bearishly below the 50-day moving average on May 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRPT as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for SRPT turned negative on May 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
SRPT moved below its 50-day moving average on May 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for SRPT moved below the 200-day moving average on June 08, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SRPT entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SRPT's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .
SRPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SRPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.074) is normal, around the industry mean (18.720). P/E Ratio (43.743) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). SRPT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.745) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of treatments for life-threatening illnesses and viruses
Industry Biotechnology